Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
AVXL
Strong SellSinkerAnavex Life Sciences Corp. · Healthcare · United States · $277M · Avg Vol: $2M/d
COMPANY DESCRIPTION
Anavex Life Sciences is a clinical-stage biopharmaceutical company developing therapeutics for neurodegenerative and neurodevelopmental diseases, with lead candidate blarcamesine targeting conditions like Alzheimer's and Rett syndrome. The company leverages a novel small molecule mechanism of action, focusing on sigma-1 and muscarinic receptor activation in areas with significant unmet medical need. It operates as a niche pipeline-driven biopharma firm, with valuation tied to clinical trial progress and regulatory approvals.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | — | — | — | — | — |
| EPS | -0.62 | -0.60 | -0.52 | -0.54 | — | -0.14 | -0.33 | -0.55 | — |
| Shares | 77.9M | 82.1M | 84.8M | 86.7M | +11.2% | 92.7M | — | — | — |
| Debt | — | — | — | — | — | — | — | — | — |
| Equity | 142.5M | 141.9M | 120.3M | 94.9M | -12.7% | — | — | — | — |
| Op CF | -24.2M | -27.8M | -30.8M | -39.0M | — | -29.3M | — | — | — |
| Inv CF | — | — | — | — | — | — | — | — | — |
| Fin CF | 21.3M | 29.7M | 12.0M | 9.4M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of AVXL are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| AVXL | Anavex Life Sciences Corp.(you) | $277M | 9 | Strong Sell |
| TRDA | Entrada Therapeutics, Inc. | $273M | 10 | Strong Sell |
| SRZN | Surrozen, Inc. | $264M | 9 | Strong Sell |
| CAMP | CAMP4 THERAPEUTICS CORPORATION | $260M | 10 | Strong Sell |
| RNAC | Cartesian Therapeutics, Inc. | $290M | 12 | Strong Sell |
| IVVD | Invivyd, Inc. | $284M | 12 | Strong Sell |
| LCTX | Lineage Cell Therapeutics, Inc. | $281M | 5 | Strong Sell |
| STRO | Sutro Biopharma, Inc. | $339M | 9 | Strong Sell |
| TARA | Protara Therapeutics, Inc. | $226M | 9 | Strong Sell |
| RNA | Atrium Therapeutics, Inc. | $233M | 11 | Strong Sell |
Peer medians: ROE -30.7% · P/E 27.0x · Gross margin 58.3%